HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

T-DXd Has Intracranial Activity in Meta-Analysis of HER2+ Breast Cancer Brain Metastases

March 8th 2024

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.

T-DXd Fails to Receive Recommendation From NICE for HER2-Low Breast Cancer Treatment

March 6th 2024

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Sammons Spotlights Approaches Under Exploration for HER2+ Breast Cancer and Brain Metastases

February 19th 2024

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast Cancer

February 15th 2024

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Real-World Analysis Sheds Light on Brain Metastases Incidence in HER2+ Breast Cancer

February 15th 2024

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

The Ongoing Investigation of GLSI-100 Continues in the Flamingo-01 Study for HER2/Neu+ Breast Cancer

February 14th 2024

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

Dr Sammons on the Investigation of Brain Metastases in HER2+ Breast Cancer

February 13th 2024

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

McAndrew Expands on the Evolving Treatment Armamentarium in HER2+ Breast Cancer

February 13th 2024

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

Dr Sammons on the Real-World Incidence of Brain Metastases in HER2+ Breast Cancer

February 5th 2024

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Dr Hafez on the Influence of Biomarker Expression on Adjuvant T-DM1 Use in HER2+ Breast Cancer

February 1st 2024

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

SABCS 2023 Findings Build on Positive Momentum in HER2+ Breast Cancer

February 1st 2024

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

Dr McAndrew on the Implications of the PHERGain Study in HER2+ Breast Cancer

February 1st 2024

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Dr McAndrew on the Evolving Treatment Armamentarium for HER2+ Breast Cancer

January 24th 2024

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.

Dr McAndrew on the Impact of the KATHERINE Trial in HER2+ Breast Cancer

January 23rd 2024

Nicholas P. McAndrew, MD, MSCE, discusses the impact of the phase 3 KATHERINE trial in patients with HER2-positive breast cancer.

Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer

January 19th 2024

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

Disitamab Vedotin Combos Show Efficacy in HER2+ and HER2-Low Breast Cancers

January 17th 2024

Disitamab vedotin alone and with ICIs, TKIs, or other antiangiogenic agents had consistent efficacy in patients with HER2-positive or -low breast cancers.

Dr D'Abreo on the Evolution of ADC Use in the HER2+ Breast Cancer Treatment Landscape

January 15th 2024

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.

Dr Hafez on Key Considerations For Treatment Selection in Early-Stage HER2+ Breast Cancer

January 12th 2024

Maria Hafez, MD, explains how hormone receptor status, risk stratification, & other factors influence clinical decisions in early HER2+ breast cancer.

Dr D'Abreo on Leveraging Biology When Treating HER2+ Breast Cancer

January 10th 2024

Nina D'Abreo, MD, discusses advances made in the treatment of patients with HER2-low and HER2-positive breast cancers.

Exploratory Analyses of KATHERINE Trial Inform Adjuvant T-DM1 Use in HER2+ Breast Cancer

December 18th 2023

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.